USA approves CRISPR therapy for the first time – how long ago was it?
The background
On December 8, 2023, the FDA approved a treatment based on the CRISPR/Cas9 gene scissors for the first time in the USA. Casgevy has been approved for certain people ages 12 and older with sickle cell disease. In this hereditary disease, deformed red blood cells can block vessels and trigger severe pain crises. For the therapy, the body's own blood stem cells are genetically modified outside the body and then returned. They are intended to promote the formation of a protective form of the blood pigment. The approval marked a step from genetic research to medical use. The procedure is not a simple injection: it requires stressful pretreatment and specialized centers. Great Britain had already approved the therapy in November; The US decision was therefore not a global first approval.